Differential Diagnosis of Erythroderma

Introduction

Erythroderma (exfoliative dermatitis) is defined as generalized erythema affecting more than 90% of the body surface area, typically accompanied by scaling. It represents a dermatologic emergency due to the profound physiological derangements that accompany widespread cutaneous inflammation. The systemic consequences include thermoregulatory dysfunction, fluid and electrolyte imbalance, protein loss, high-output cardiac failure, and increased susceptibility to infection.

The clinical challenge lies not merely in recognizing erythroderma but in identifying its underlying cause, as treatment is cause-specific. In approximately 20-30% of cases, no cause is identified despite thorough workup—these are termed "idiopathic" but require long-term surveillance for emergence of underlying malignancy or late diagnosis of a primary dermatosis.

---

20.1 Epidemiology

• Incidence: Rare. Estimated at 1-2 per 100,000 population per year.
• Age: Mean age of onset is 40-60 years.
• Sex: Male predominance (2-4:1).

---

20.2 Pathophysiology of Systemic Complications

Understanding the pathophysiology guides supportive management, which is as critical as addressing the underlying cause.

20.2.1 Thermoregulation

• Vasodilation: Massive cutaneous blood flow increases (up to 90% of cardiac output may be directed to skin).
• Heat Loss: Impaired insulation due to damaged skin barrier.
• Result: Patients may be hypothermic OR hyperthermic depending on ambient temperature and fever from underlying cause.

20.2.2 Fluid and Electrolyte Imbalance

• Transepidermal Water Loss (TEWL): Increased up to 10-20 fold due to disrupted stratum corneum.
• Dehydration: High-output renal failure, prerenal azotemia.
• Electrolyte Derangement: Hyponatremia, Hypokalemia.

20.2.3 Protein Loss

• Scaling: Continuous exfoliation leads to significant protein loss (up to 25-30 g/day).
• Consequence: Hypoalbuminemia → Peripheral edema, impaired wound healing, negative nitrogen balance.

20.2.4 Cardiovascular Stress

• High-Output State: Increased cardiac output to maintain skin perfusion.
• Cardiac Failure: Particularly in elderly or those with pre-existing heart disease.

20.2.5 Infection Risk

• Skin Barrier Breach: Entry point for pathogens.
• Erythrodermic patients are at high risk for Staphylococcal sepsis.

---

20.3 Major Etiologies

20.3.1 Pre-Existing Dermatoses (~50% of Cases)

The most common cause overall. Erythroderma represents an exacerbation or generalization of a known skin condition.

Psoriasis

• Most common cause of erythroderma in many series (~25%).
• History: Known psoriasis, often with triggers such as:
  • Abrupt withdrawal of systemic steroids
  • Infection
  • Drug triggers (lithium, beta-blockers, antimalarials)
  • Phototherapy burns
• Clinical Clues:
  • Nail changes: Pitting, oil spots, onycholysis, subungual hyperkeratosis.
  • Scalp involvement with well-demarcated silvery plaques.
  • Joint involvement (psoriatic arthritis).
  • Family history.
• Histology: May be non-specific in erythrodermic state. Psoriasiform hyperplasia, munro microabscesses, loss of granular layer (may be lost).

Atopic Dermatitis / Eczema

• Second most common cause.
• History: Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis). Childhood onset of eczema.
• Clinical Clues:
  • Lichenification in flexural areas.
  • Intense pruritus.
  • Dry skin with ichthyosiform changes.
  • Dennie-Morgan folds, allergic shiners.

Seborrheic Dermatitis

• Can generalize to erythroderma, especially in HIV/AIDS patients.
• Clinical Clues: Scalp and facial predominance with greasy, yellowish scale.

Pityriasis Rubra Pilaris (PRP)

• A classic cause of erythroderma with distinctive features.
• Key Features:
  • "Islands of Sparing": Areas of uninvolved skin within erythroderma (pathognomonic).
  • Orange-Red Hue: Distinctive color.
  • Palmoplantar Keratoderma: Waxy, yellow-orange thickening of palms and soles with sharp demarcation.
  • Follicular Plugging: Follicular papules with central keratotic plugs on dorsum of fingers.
• Classification: Types I-V (Type I classical adult most common).

Contact Dermatitis (Generalized)

• Usually from widespread application of allergen or systemic contact dermatitis (e.g., ingestion of allergen to which patient is sensitized).
• History: Exposure to topical agents (neomycin, fragrances, preservatives) or systemic drugs chemically related to contact allergens.

---

20.3.2 Drug-Induced Erythroderma (~25% of Cases)

[!IMPORTANT] Always take a detailed drug history extending back 6-8 weeks.

Drug-induced erythroderma can range from simple morbilliform eruption that generalizes to life-threatening DRESS syndrome.

Common Culprit Drugs

DRESS Syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms)

[!CAUTION] Life-Threatening Drug Reaction

• Onset: 2-8 weeks after starting drug (longer than simple drug eruption).
• Features:
  • Erythroderma or extensive morbilliform eruption.
  • Facial Edema (distinctive).
  • Lymphadenopathy (generalized).
  • Eosinophilia (>1500/μL) or atypical lymphocytosis.
  • Internal Organ Involvement: Hepatitis (most common), nephritis, pneumonitis, myocarditis.
  • Fever (often high).
• HHV-6 Reactivation: Associated with DRESS.
• Mortality: 5-10%.
• Management: Withdraw offending drug. Systemic corticosteroids. Supportive care.

---

20.3.3 Malignancy (~10-15% of Cases)

Cutaneous T-Cell Lymphoma (Sézary Syndrome)

• Definition: Leukemic variant of CTCL characterized by erythroderma, lymphadenopathy, and circulating malignant T-cells.
• Clinical Features:
  • Generalized erythroderma with intense pruritus.
  • Marked edema, especially of face ("leonine facies").
  • Lymphadenopathy.
  • Palmoplantar keratoderma.
  • Alopecia, nail dystrophy.
• Key Finding: Sézary Cells in peripheral blood—atypical lymphocytes with cerebriform (convoluted) nuclei.
• Diagnosis:
  • Peripheral blood smear: Sézary cells.
  • Flow cytometry: CD4+ T-cells with loss of CD7 or CD26. CD4:CD8 ratio >10.
  • T-cell receptor gene rearrangement: Clonality in blood and skin.
• Prognosis: Poor. Median survival 2-4 years.

Other Malignancies

• Hodgkin and Non-Hodgkin Lymphoma.
• Leukemia (rare).
• Solid organ malignancy (paraneoplastic erythroderma - rare).

---

20.3.4 Idiopathic Erythroderma (~20%)

• No identifiable cause despite comprehensive workup.
• Approach:
  • Skin biopsy (multiple, from different sites).
  • Drug history review.
  • Exclude malignancy (CT, flow cytometry, lymph node biopsy if indicated).
  • Long-term surveillance: Repeat biopsies. Idiopathic erythroderma may evolve into CTCL over months to years.

---

20.4 Clinical Approach to Erythroderma

20.4.1 History

• Prior skin disease: Psoriasis, eczema, seborrheic dermatitis, PRP, contact allergy.
• Drug history: Complete list of all medications (prescribed, OTC, herbal) with timing.
• Systemic symptoms: Fever, night sweats, weight loss (suggests malignancy).
• Pruritus: Severe pruritus with lymphadenopathy → think Sézary syndrome.

20.4.2 Physical Examination

• Skin:
  • Color and character of erythema (orange-red in PRP, salmon-pink in psoriasis).
  • Presence of "islands of sparing" (PRP).
  • Mucosal involvement (suggests drug reaction).
  • Palmoplantar keratoderma (psoriasis, PRP, Sézary).
• Nails: Pitting (psoriasis), dystrophy.
• Scalp: Greasy scale (seborrheic), silvery scale (psoriasis).
• Lymph Nodes: Generalized lymphadenopathy → consider CTCL, DRESS.
• Vital Signs: Hypothermia/hyperthermia, tachycardia.
• Edema: Peripheral, facial.

20.4.3 Investigations

---

20.5 Management Principles (General Supportive Care)

[!IMPORTANT] Erythroderma requires inpatient management in most cases.

1. Temperature Regulation: Warm room, avoid drafts.
2. Fluid and Electrolyte Replacement: IV fluids, monitor electrolytes.
3. Nutrition: High-protein diet to counter protein loss.
4. Emollients: Frequent application of bland emollients to reduce TEWL.
5. Topical Steroids: Low-to-mid potency initially. Avoid high potency over large areas (systemic absorption).
6. Monitor for Cardiac Failure: Especially in elderly.
7. Infection Prevention/Treatment: Barrier nursing. Low threshold for antibiotics if signs of sepsis.

---

20.6 Diagnostic Algorithm

Loading diagram...

---

20.7 Comparative Features Table

---

20.8 Clinical Pearls

1. Psoriasis is the most common cause of erythroderma but nails, scalp, and prior history are key to diagnosis.
2. PRP has "islands of sparing"—if you see uninvolved skin within widespread erythema, think PRP.
3. Drug eruption timeline: Simple drug rash = 7-14 days. DRESS = 2-8 weeks.
4. Facial edema + Lymphadenopathy + Eosinophilia = DRESS until proven otherwise.
5. Sézary syndrome: Suspect if erythroderma + severe pruritus + lymphadenopathy. Order peripheral smear and flow cytometry.
6. "Idiopathic" erythroderma requires long-term follow-up—a proportion will eventually declare as CTCL.
7. Supportive care is critical: Patients can die from complications (hypothermia, sepsis, cardiac failure) regardless of etiology.